Enthea, the healthcare provider that specializes in psychedelic therapy, announced on Tuesday that it will “launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and provider network to further its mission of providing affordability and access to safe and effective psychedelic-assisted therapies for all who can benefit.”

The ambitious launch is the byproduct of a “successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups,” the company said in the announcement.

Enthea says that the driving force behind the new endeavor is to improve access to potentially breakthrough psychedelic treatment amid an ever-spiraling mental health crisis in the United States.

The company asserts that it is “helping in this mental health crisis by bringing employer funding for these new treatments,” saying that “traditional health insurers are years away from adding this coverage, the cost

The U.S. Senate on Wednesday approved landmark legislation to expand medical marijuana research, marking the first time both chambers of Congress have passed a standalone cannabis bill. The measure, titled the Medical Marijuana and Cannabidiol Research Expansion Act, received the approval of the House of Representatives during the summer and now heads to the desk of President Joseph Biden for his consideration.

Democratic Representative Earl Blumenauer of Oregon, the co-sponsor of the legislation in the House along with Maryland Republican Representative Andy Hariss, noted the significance of the legislation after the Senate vote on Wednesday.

“After working on the issue of cannabis reform for decades, finally the dam is starting to break. The passage of my Medical Marijuana and Cannabidiol Research Expansion Act in the House and Senate represents a historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis,” Blumenauer, the founder and co-chair of the